Copley Scientific has announced the launch of its new BAC 200iX breath actuation controller for use in aerodynamic particle size distribution and delivered dose uniformity testing of MDIs, DPIs, SMIs, and nebulizers. The announcement notes that the BAC 200iX can be connected with the company’s Inhalytix+ cascade impaction software package, the latest version of which launched in September 2026 along with a new critical flow controller.
Other products that Copley has launched this year include a new Inhaled Dissolution Apparatus (IDA) for dissolution testing of OINDPs and the SRS 100i automated sample recovery system for use with delivered dose uniformity and APSD testing systems.
Copley Head of Business Development Paul Martin commented, “Our priority with the BAC 200iX was to make routine inhaler testing more straightforward while strengthening control over how tests are set up, executed, and recorded. We’ve focused on practical enhancements that help laboratories maintain consistent procedures and meet the demands of regulated testing.”
Martin added, “With the BAC 200iX joining the recently launched Critical Flow Controller TPK 200iXf, laboratories now have a choice of next-generation flow controllers suited to different testing requirements. Importantly, both instruments offer enhanced control and traceability as standalone solutions, with the option to extend these capabilities through Inhalytix+ for centralized management across the wider laboratory workflow.”
Read the Copley Scientific press release






